Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

Valentina Svicher; Claudia Alteri; Caterina Gori; Romina Salpini; Fabbio Marcuccilli; Ada Bertoli; Roberta Longo; Martina Bernassola; Valentina Gallinaro; Sara Romano; Michela Visca; Antonella Ursitti; Marcello Feasi; Valeria Micheli; Mario Angelico; Giovanni Cassola; Giustino Parruti; Guido Gubertini; Giuseppe Maria De Sanctis; Francesca Ceccherini-Silberstein; Giuseppina Cappiello; Alberto Spanò; Carlo Federico Perno

doi:10.1016/j.dld.2010.04.017

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

Valentina Svicher, Claudia Alteri, Caterina Gori, Romina Salpini, Fabbio Marcuccilli, Ada Bertoli, Roberta Longo, Martina Bernassola, Valentina Gallinaro, Sara Romano, Michela Visca, Antonella Ursitti, Marcello Feasi, Valeria Micheli, Mario Angelico, Giovanni Cassola, Giustino Parruti, Guido Gubertini, Giuseppe Maria De Sanctis, Francesca Ceccherini-SilbersteinGiuseppina Cappiello, Alberto Spanò, Carlo Federico Perno

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345. IU/ml) or when HBV-DNA is undetectable. Methods: Sixty-four HBV-mono-infected patients were enrolled: 25 had virological breakthrough with serum HBV-DNA ranging from 12 to 345. IU/ml during first-line LAM-monotherapy; 24 were on LAM-monotherapy, and 15 were on LAM. +. adefovir dipivoxil (ADV) with undetectable serum HBV-DNA (

Original language	English
Pages (from-to)	902-907
Number of pages	6
Journal	Digestive and Liver Disease
Volume	42
Issue number	12
DOIs	https://doi.org/10.1016/j.dld.2010.04.017
Publication status	Published - Dec 2010

Keywords

Drug resistance
HBV
Low viral replication

ASJC Scopus subject areas

Gastroenterology
Hepatology

Access to Document

10.1016/j.dld.2010.04.017

Cite this

Svicher, V., Alteri, C., Gori, C., Salpini, R., Marcuccilli, F., Bertoli, A., Longo, R., Bernassola, M., Gallinaro, V., Romano, S., Visca, M., Ursitti, A., Feasi, M., Micheli, V., Angelico, M., Cassola, G., Parruti, G., Gubertini, G., De Sanctis, G. M., ... Perno, C. F. (2010). Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. Digestive and Liver Disease, 42(12), 902-907. https://doi.org/10.1016/j.dld.2010.04.017

Svicher, V, Alteri, C, Gori, C, Salpini, R, Marcuccilli, F, Bertoli, A, Longo, R, Bernassola, M, Gallinaro, V, Romano, S, Visca, M, Ursitti, A, Feasi, M, Micheli, V, Angelico, M, Cassola, G, Parruti, G, Gubertini, G, De Sanctis, GM, Ceccherini-Silberstein, F, Cappiello, G, Spanò, A & Perno, CF 2010, 'Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia', Digestive and Liver Disease, vol. 42, no. 12, pp. 902-907. https://doi.org/10.1016/j.dld.2010.04.017

@article{d1d58935e80e43f8a688e1f9d0c0cbb8,

title = "Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia",

abstract = "Objective: To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345. IU/ml) or when HBV-DNA is undetectable. Methods: Sixty-four HBV-mono-infected patients were enrolled: 25 had virological breakthrough with serum HBV-DNA ranging from 12 to 345. IU/ml during first-line LAM-monotherapy; 24 were on LAM-monotherapy, and 15 were on LAM. +. adefovir dipivoxil (ADV) with undetectable serum HBV-DNA (",

keywords = "Drug resistance, HBV, Low viral replication",

author = "Valentina Svicher and Claudia Alteri and Caterina Gori and Romina Salpini and Fabbio Marcuccilli and Ada Bertoli and Roberta Longo and Martina Bernassola and Valentina Gallinaro and Sara Romano and Michela Visca and Antonella Ursitti and Marcello Feasi and Valeria Micheli and Mario Angelico and Giovanni Cassola and Giustino Parruti and Guido Gubertini and {De Sanctis}, {Giuseppe Maria} and Francesca Ceccherini-Silberstein and Giuseppina Cappiello and Alberto Span{\`o} and Perno, {Carlo Federico}",

year = "2010",

month = dec,

doi = "10.1016/j.dld.2010.04.017",

language = "English",

volume = "42",

pages = "902--907",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "Elsevier B.V.",

number = "12",

}

TY - JOUR

T1 - Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

AU - Svicher, Valentina

AU - Alteri, Claudia

AU - Gori, Caterina

AU - Salpini, Romina

AU - Marcuccilli, Fabbio

AU - Bertoli, Ada

AU - Longo, Roberta

AU - Bernassola, Martina

AU - Gallinaro, Valentina

AU - Romano, Sara

AU - Visca, Michela

AU - Ursitti, Antonella

AU - Feasi, Marcello

AU - Micheli, Valeria

AU - Angelico, Mario

AU - Cassola, Giovanni

AU - Parruti, Giustino

AU - Gubertini, Guido

AU - De Sanctis, Giuseppe Maria

AU - Ceccherini-Silberstein, Francesca

AU - Cappiello, Giuseppina

AU - Spanò, Alberto

AU - Perno, Carlo Federico

PY - 2010/12

Y1 - 2010/12

N2 - Objective: To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345. IU/ml) or when HBV-DNA is undetectable. Methods: Sixty-four HBV-mono-infected patients were enrolled: 25 had virological breakthrough with serum HBV-DNA ranging from 12 to 345. IU/ml during first-line LAM-monotherapy; 24 were on LAM-monotherapy, and 15 were on LAM. +. adefovir dipivoxil (ADV) with undetectable serum HBV-DNA (

AB - Objective: To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345. IU/ml) or when HBV-DNA is undetectable. Methods: Sixty-four HBV-mono-infected patients were enrolled: 25 had virological breakthrough with serum HBV-DNA ranging from 12 to 345. IU/ml during first-line LAM-monotherapy; 24 were on LAM-monotherapy, and 15 were on LAM. +. adefovir dipivoxil (ADV) with undetectable serum HBV-DNA (

KW - Drug resistance

KW - HBV

KW - Low viral replication

UR - http://www.scopus.com/inward/record.url?scp=78650286696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650286696&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2010.04.017

DO - 10.1016/j.dld.2010.04.017

M3 - Article

C2 - 20621632

AN - SCOPUS:78650286696

SN - 1590-8658

VL - 42

SP - 902

EP - 907

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

IS - 12

ER -

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this